Regeneron looks to target most in-need patients for Covid drug

Regeneron said on Thursday it was working to address questions over how to target the most in-need patients for its antibody treatment for Covid-19, which US president Donald Trump said was a “cure” for the disease. The treatment could be approved for emergency use in the “relatively near future”, Leonard Schleifer, Regeneron’s chief executive, told analysts in a discussion of its latest earnings. The New York-based biotech said it will have 80,000 doses available by the end of the month, and 300,000 by the end of January. But the number of Covid-19 patients who could benefit from the drug, if approved, is soaring, with 100,000 cases reported in the US in a single day on Wednesday for the first time.